A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 851-861

  Te, Alexis E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alpha adrenergic receptor antagonist; Benign prostatic hyperplasia; Brachytherapy; Phenoxybenzamine; Pheochromocytoma; Urogenital surgery

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PHENOXYBENZAMINE; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ADRENERGIC ACTIVITY; ADULT; AGED; ALPHA ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTONOMIC DYSREFLEXIA; BRACHYTHERAPY; CARCINOGENICITY; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED STUDY; DIAPHORESIS; DOSE RESPONSE; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MEDLINE; MENINGOMYELOCELE; NEUROGENIC BLADDER; NONHUMAN; NOSE CONGESTION; PATHOGENESIS; PHEOCHROMOCYTOMA; PROSTATE HYPERTROPHY; PROSTATITIS; RAT; REVIEW; SYMPTOM; URINARY TRACT DISEASE; VERTIGO; ANIMAL; CLINICAL TRIAL; HALF LIFE TIME; TISSUE DISTRIBUTION; URINARY TRACT INFECTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CLINICAL TRIALS; HALF-LIFE; HUMANS; MALE; PHENOXYBENZAMINE; PROSTATIC HYPERPLASIA; RATS; TISSUE DISTRIBUTION; URINARY TRACT INFECTIONS;

EID: 0036308558     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80003-0     Document Type: Article

References (25)

1. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia
2. Bladder outflow obstruction treated with phenoxybenzamine
3. Phenoxybenzamine for benign prostatic obstruction: Review of 200 cases
4. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction
5. Comparative study of therapeutic effect of dibenzyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia
6. Phenoxybenzamine in prostatic obstruction
7. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia: A urodynamic investigation
8. Management of neurogenic bladder dysfunction secondary to myelomeningocele
9. Urodynamic studies in evaluating detrusor sphincter dyssynergia and their effects on the treatment
10. Autonomic dysreflexia. A survey of current treatment
11. Phenoxybenzamine in neurogenic bladder dysfunction after spinal cord injury. II. Autonomic dysreflexia
12. Alpha-adrenergic blocker for posthernioplasty urinary retention: Prevention and treatment
13. Prophylactic phenoxybenzamine in the prevention of post-operative retention of urine after vaginal repair: A prospective randomized double-blind trial
14. 125iodine implantation for localized carcinoma of the prostate
15. 125iodine implantation for treatment of clinically localized prostate cancer: 5-Year tumor control and morbidity
16. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
17. Temporal resolution of urinary morbidity following prostate brachytherapy
18. Phenoxybenzamine in the treatment of causalgia. Report of 40 cases
19. Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): Management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients
20. Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy
21. Alpha-difluoromethylornithine (alpha DFMO) and phenoxybenzamine hydrochloride in the treatment of chronic non-suppurative prostatitis
22. Adrenoceptor antagonist drugs
23. Adrenoceptor-activating and other sympathomimetic drugs
24. Adrenoceptor pharmacology: Urogenital applications
25. Carcinogenic properties of certain rubber additives